Aberrant expression of breast development-related microRNAs, miR-22, miR-132, and miR-212, in breast tumor tissues by Damavandi, Z. et al.
© 2016 Korean Breast Cancer Society. All rights reserved. http://ejbc.kr  |  pISSN 1738-6756 
eISSN 2092-9900This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ 
licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Breast cancer is a heterogeneous and complex genetic dis-
ease that is characterized by altered expression of several cod-
ing and noncoding genes. Despite recent advances in early 
detection and therapies, breast cancer is still the leading cause 
of cancer related death among women worldwide. For that 
reason, unraveling the molecular mechanisms underlying the 
initiation and progression of breast tumors may lead to prom-
ising translations towards better diagnoses, prognoses, and 
targeted therapies [1].
The accumulation of a variety of genetic and epigenetic al-
terations in somatic cells can drive tumorigenesis in different 
tissues. Among the genetic changes, gene amplification and 
deletions are most frequently observed in several kinds of 
cancers. Specifically, the amplification of oncogenes and dele-
tion of tumor suppressor genes have been investigated in ge-
nome-wide analyses, which have revealed some of the mech-
anisms of carcinogenesis. Similar to other cancers, breast can-
cer is initiated by a progressive accumulation of genetic and 
epigenetic aberrations [2,3].
Loss of heterozygosity (LOH) on the short arm of chromo-
some 17 (17p) is a frequent event in breast cancer, where dele-
tions in 17p are observed in 49% of breast cancers [2]. Partic-
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Purpose: MicroRNAs (miRNAs) are a major class of small en-
dogenous RNA molecules that posttranscriptionally regulate the 
expression of most genes in the human genome. miRNAs are 
often located in chromosomal fragile sites, which are suscept-
ible to amplification or deletion. Chromosomal deletions are fre-
quent events in breast cancer cells. Deletion and loss of hetero-
zygosity at 17p13.3 have been reported in 49% of breast can-
cers. The aim of the current study was to evaluate potential ex-
pression alterations of miR-22, miR-132, and miR-212, which 
are located on the 17p13.3 locus and are required for mammary 
gland development. Methods: A matched case-control study 
was conducted, which included 36 pairs of tumor and matched 
nontumor surgical specimens from patients diagnosed with 
breast invasive ductal carcinoma. Formalin-fixed paraffin-em-
bedded samples from archival collections at the pathology de-
partment of Shariati Hospital were prepared for RNA extraction 
using the xylene-ethanol method before total RNA was isolated 
with TRIzol Reagent. Specific primers were designed for cDNA 
synthesis and miRNA amplification. The expression of miRNAs 
was then evaluated by real-time polymerase chain reaction (RT-
PCR). Results: According to our RT-PCR data, the miR-212/
miR-132 family was downregulated in breast cancer (0.328-fold, 
p<0.001), and this reduced expression was the most prominent 
in high-grade tumors. In contrast, miR-22 exhibited a significant 
upregulation in breast tumor samples (2.183-fold, p=0.040). 
Conclusion: Consistent with the frequent deletion of the 17p13.3 
locus in breast tumor cells, our gene expression data demon-
strated a significant downregulation of miR-212 and miR-132 in 
breast cancer tissues. In contrast, we observed a significant 
upregulation of miR-22 in breast tumor samples. The latter con-
flicting result may have been due to the upregulation of miR-22 
in stromal/cancer-associated fibroblasts, rather than in the tu-
mor cells.
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ularly, in several LOH studies, a high frequency of deletions in 
two distinct regions of 17p (17p13.1 and 17p13.3) have been 
reported. The p53 tumor suppressor gene is located on chro-
mosome band 17p13.1, and it is thought that the 17p13.3 re-
gion encodes other tumor suppressor genes with potential 
regulatory roles in tumorigenesis [2,4,5]. 
Three microRNAs (miRNAs), namely miR-22 and the miR-
212/132 family, have been identified in the chromosomal re-
gion 17p13.3, and are involved in normal breast tissue devel-
opment. These miRNAs have vital roles in normal develop-
mental processes such as epithelial-stromal interactions and 
expansion of mammary progenitor cell populations [6-8]. 
miRNAs are a new class of endogenous, small (19–25 nucleo-
tide length), noncoding RNAs, which posttranscriptionally 
regulate gene expression. miRNAs are evolutionarily con-
served, and are involved in several developmental and cellular 
processes including the cell cycle, cell proliferation, and tu-
morigenesis [9]. The discovery of miRNAs has also led to new 
strategies for disease diagnosis and therapy [10]. 
miRNAs exert their functions primarily by targeting the 3´  
untranslated region of their target messenger RNAs (mRNAs), 
by which they induce translational silencing, either by cleav-
ing the mRNA or blocking translation. Therefore, miRNAs 
may act as either tumor suppressor genes or oncogenic miRNAs 
(oncomiRs) in various types of cancers [11,12]. Several studies 
have revealed that there is aberrant expression of miRNAs in 
breast cancer initiation and progression. Moreover, several 
miRNAs have been considered as potential tumor markers for 
breast cancer [13,14].
In the present study, we evaluated the expression of miR-22, 
miR-132, and miR-212 in tumor and nontumor breast tissues. 
Moreover, we investigated whether expression alterations in 
these miRNAs were correlated with the malignant state of the 
tumors. 
METHODS
Human clinical samples
Formalin-ﬁxed parafﬁn-embedded (FFPE) tissues were 
obtained from the pathology center of Shariati Hospital in 
Tehran, Iran. The tissues were collected from female patients 
with invasive ductal carcinoma as determined through evalu-
ation of histopathological parameters according to the World 
Health Organization (WHO) criteria for histologic grade and 
the TNM system for stage classiﬁcation. A total of 36 tumor 
samples and 36 matched nontumor samples from the same 
patients were obtained for this study. This study was approved 
(#91715) by the Ethics Committee of Tarbiat Modares Uni-
versity, Tehran, Iran. 
RNA extraction, complimentary DNA synthesis, and real-time 
polymerase chain reaction
RNA extraction from FFPE samples can be troublesome 
because of different chemical modifications and degradation 
over time. Specifically, in FFPE samples, the RNA is heavily 
degraded during the fixation process, fragment lengths vary 
from single bases to several hundred bases, and thus the yield 
of RNA extracted from FFPE tissues is much lower than that 
from fresh tissues. Paraffin from FFPE tissue sections was re-
moved by the xylene-ethanol method, and then total RNA 
was isolated using TRIzol Reagent (Invitrogen, Paisley, UK) 
according to the manufacturer’s instructions. The RNA yield 
and A260/280 ratio were determined by a NanoDrop spectro-
photometer (Thermo Fisher Scientific, Waltham, USA). 
Subsequently, the samples were treated with RNase-free DNase 
to remove possible traces of genomic DNA. Complimentary 
DNA (cDNA) synthesis was then performed on 2 µg total 
RNA using the MiR-Amp Kit (ParsGenome, Tehran, Iran), in 
which the polyA tailing method with syn primers was used to 
synthesize specific cDNA from miRNAs. Briefly, the samples 
were incubated for 10 minutes at 37°C to form the polyA tails. 
Next, the samples were incubated for 60 minutes at 43°C. 
Lastly, heat-inactivation of reverse transcriptase was carried 
out by incubation for 1 minute at 85°C. 
Real-time polymerase chain reaction (RT-PCR) was per-
formed using 1 μL cDNA product, miR-specific primers, and 
EvaGreen dye (Biotium, Hayward, USA). The 5s rRNA gene 
was used as an internal control. RT-PCR was carried out in an 
ABI-7500 real-time quantitative PCR instrument (Applied 
Biosystems, Foster City, USA) with the following conditions: 
95°C for 15 minutes, followed by 40 cycles of 95°C for 15 sec-
onds, 63°C for 25 seconds, and 72°C for 35 seconds. All RT-
PCR amplifications were performed in duplicate, and a nega-
tive control was included for each reaction for quality control.
Product verification
The authenticity of the amplified RT-PCR products was 
evaluated by the following two methods: agarose gel electro-
phoresis and DNA sequencing. Due to the small length of 
miRNAs, cloning is necessary for accurate sequencing, and 
thus TA cloning was carried out using the InsTAclone PCR 
Cloning Kit (Fermentas, Hanover, USA) prior to sequencing.
Statistical analyses
The reaction efficiencies for each primer pair were deter-
mined by LinRegPCR software (Academic Medical Centre, 
Amsterdam, The Netherlands). RT-PCR data analyses were 
performed with REST 2009 software (Qiagen, Hilden, Germany) 
and GraphPad Prism 6 software (GraphPad Software Inc., San 
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Diego, USA). The miRNA expression levels in each sample 
were normalized to those of 5s rRNA. Then, normalized 
miRNA expression levels in the tumor samples were normal-
ized to those of the matched nontumor samples, by using the 
2-ΔΔCt method. The results were analyzed by performing Stu-
dent t-tests, with p< 0.05 considered statistically significant. 
All experiments were carried out at least two times. Samples 
with a two threshold cycle difference across duplicates were 
discarded from gene expression analyses. 
RESULTS
We used speciﬁc primers and a quantitative RT-PCR ap-
proach to amplify miRNAs located in the 17p13.3 chromo-
somal region, which is frequently deleted in breast cancer. Af-
ter the addition of polyA tails to the given miRNAs, universal 
and miR-specific primers amplified ~70 base pair products. 
The uniqueness and authenticity of the amplified products 
were confirmed by agarose gel electrophoresis, the presence of 
Figure 1. Uniqueness and authenticity of the real-time polymerase chain reaction (RT-PCR) products. (A) The size and uniqueness of miR-22, miR-
132, miR-212, and 5s rRNA PCR products following agarose gel electrophoresis. (B) The authenticity of the PCR amplified products is shown by sin-
gle, sharp melting curves.
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single, sharp melting curves, and direct DNA sequencing 
(Figure 1).
miR-132 is significantly downregulated in breast tumors
We determined the relative expression of miR-132 in 36 
paired tumor/nontumor FFPE breast tissue samples. The rela-
tive expression levels of miR-132, adjusted to those of the 5s 
rRNA internal control, in tumor samples were normalized to 
those of the nontumor controls obtained from the same pa-
tient. Our data revealed that there was a significant downreg-
ulation of miR-132 expression levels in tumor samples (0.328-
fold decrease in expression) compared to those of their 
matched nontumor controls (p < 0.001) (Figure 2A). As 
shown in Figure 2B, a noticeable decrease in miR-132 expres-
sion was also observed in high histologic grade tumors com-
pared to that of tumor samples with low histologic grade. 
However, this observed difference was not statistically signifi-
cant, which may have been due to the small sample size (20 
samples of high-grade tumors and 16 samples of low-grade 
tumors). Similarly, the levels of miR-132 expression in stage 
III tumors were higher than those in stages Ӏ and II tumors 
(Figure 2C). Nevertheless, this observed difference was also 
not statistically significant. We also employed a receiver oper-
ating characteristic (ROC) curve analysis to evaluate the sen-
sitivity and specificity of miR-132 expression to discriminate 
between tumor and nontumor breast tissue samples. The total 
area under the curve (AUC) for miR-132 expression was 73% 
(p< 0.001), suggesting that it may be suitable as a potential tu-
mor marker for breast cancer (Figure 2D). 
miR-212 is significantly downregulated in breast tumors 
We determined the relative expression of miR-212 in 31 
paired tumor/nontumor FFPE breast tissue samples. The rela-
tive expression levels of miR-212, adjusted to those of 5s rRNA, 
Figure 2. miR-132 expression in tumor versus nontumor breast tissue samples. The expression levels of miR-132 were normalized to those of the 5s 
rRNA internal control. (A) Histograms show the mean values of relative miR-132 expression in tumor and nontumor samples, with confidence intervals 
as the error bars. Note that the expression of miR-132 was significantly lower in tumor tissues than that in the corresponding nontumor tissues ob-
tained from the same patients (p=0.001). Comparative expression levels of miR-132 are presented for different grades (B) and stages (C) of breast 
tumor samples. Note that the observed differences in expression were not statistically significant. (D) Receiver operating characteristic (ROC) curve 
analysis of the specificity and sensitivity of miR-132 expression in discriminating between tumor and nontumor breast tissue samples. The calculated 
area under the curve (73%) suggests that miR-132 may be suitable as a tumor marker for breast cancer. *Represents p<0.05.
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in tumor samples were normalized to those of nontumor 
specimens obtained from the same patient. A significant 
downregulation of miR-212 expression levels was observed in 
tumor samples (0.281-fold decrease in expression) compared 
to those of their matched nontumor controls (p= 0.043) (Fig-
ure 3A). Similar to miR-132, the apparent expression altera-
tions of miR-212 were not statistically associated with tumor 
grades (Figure 3B) or stages (Figure 3C). Compared to miR-
132, the ROC curve analysis revealed a lower sensitivity and 
specificity for miR-212 expression (AUC= 63%, p= 0.061) to 
discriminate between tumor and nontumor breast tissue sam-
ples (Figure 3D). 
miR-22 is significantly upregulated in breast tumors 
Our data revealed that there was a significant upregulation 
of miR-22 expression levels in tumor samples (2.183-fold in-
crease in expression) compared to those of their matched 
nontumor controls (p= 0.040) (Figure 4A). As shown in Fig-
ure 4B, a noticeable decrease in the expression of miR-22 was 
observed in high-grade tumors compared to that in low-grade 
tumors. However, this observed difference was not statistically 
significant, which may have been due to the small sample size 
(20 samples of high-grade tumors and 16 samples of low-
grade tumors). In contrast, miR-22 expression levels in stage 
III tumors were higher than those in stages I and II tumors 
(Figure 4C). Nevertheless, this observed difference was also 
not statistically significant. ROC curve analysis revealed an 
AUC of 64% (p= 0.047) for miR-22 expression in discrimi-
nating between tumor and nontumor breast tissue samples, 
suggesting that it may be moderately suitable as a potential 
marker for breast cancer (Figure 4D).
Figure 3. miR-212 expression in tumor versus nontumor breast tissue samples. The expression levels of miR-212 were normalized to those of the 5s 
rRNA internal control. (A) Histograms show the mean values of relative miR-212 expression in tumor and nontumor samples, with confidence intervals 
as the error bars. As shown, the expression of miR-212 is significantly downregulated in tumor samples (p=0.043) compared to that in nontumor 
controls. Comparative expression levels of miR-212 are presented for different grades (B) and stages (C) of breast tumor samples. Note that the ob-
served differences in expression were not statistically significant. (D) Receiver operating characteristic (ROC) curve analysis revealed an area under the 
curve of 63% for miR-212, suggesting it has moderate sensitivity and specificity to discriminate between tumor and nontumor breast tissue samples. 
*Represents p<0.05.
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Figure 4. miR-22 expression in tumor versus nontumor breast tissue samples. The expression levels of miR-22 were normalized to those of the 5s 
rRNA internal control. (A) Histograms show the mean values of relative miR-22 expression in tumor and nontumor samples, with confidence intervals 
as the error bars. Note that the expression of miR-22 was significantly higher than that in the corresponding nontumor tissues from the same patients 
(p=0.04). Comparative expression levels of miR-22 are presented for different grades (B) and stages (C) of breast tumor samples. The observed dif-
ferences in expression were not statistically significant between groups. (D) Receiver operating characteristic (ROC) curve analysis revealed an area 
under the curve of 64% for miR-22, indicating that miR-22 is a potential tumor marker with moderate specificity and sensitivity to discriminate be-
tween tumor and nontumor breast tissue samples. *Represents p<0.05.
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DISCUSSION
Deletions or LOH are frequent events in cancers. For in-
stance, frequent deletions in 17p13.3 have been reported for 
breast cancer [2,4,5]. It is postulated that at least one or two 
tumor suppressor genes reside within this region [4]. As three 
breast development-related miRNAs, namely miR-132, miR-
212, and miR-22, are located within this region, we hypothe-
sized that theses miRNAs may have tumor suppressor roles in 
breast tumorigenesis. Thus, we expected to observe downreg-
ulation of these miRNAs in breast tumor tissues.
Recently, both downregulated and upregulated expression 
of miR-132, miR-212, and miR-22 have been reported for dif-
ferent malignancies. These prior investigations have suggested 
that the aforementioned miRNAs can act as either oncogenes 
or tumor suppressor genes by targeting different mRNAs in 
multiple cellular pathways [15-21]. The versatile expression 
patterns of these miRNAs in various cancers point to their di-
verse cellular functions and the difficulty in determining their 
regulation and potential targets.
In the current study, we found that the miRNAs of interest 
were expressed in all tumor and nontumor samples. As ex-
pected, a significant downregulation of miR-132 and miR-212 
was observed in breast tumor samples, suggesting that they 
have potential tumor-suppressor roles in breast tumorigenesis. 
These results are in contrast with those in a report by Park et 
al. [19], in which increased expression of both these miRNAs 
was observed in pancreatic cancer. However, our data are con-
sistent with those of Zhang et al. [22], whose findings demon-
strated the downregulation of miR-132 in pancreatic cancer. 
One logical explanation for the conflicting reports on miRNA 
expression in similar cancer types may be that they were the 
*
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result of using samples with different stages or grades of ma-
lignancy. As we have shown here, the expression levels of 
these miRNAs varied greatly in different grade and stage sub-
groups. Interestingly, the pattern of expression in the different 
grade and stage subgroups was very similar for miR-132 and 
miR-212, which both differed from that of miR-22. This ob-
servation seems to be associated with the chromosomal loca-
tions of these miRNAs. Specifically, while miR-132 (17: 
1953202–1953302) and miR-212 (17:1953565–1953674) are 
closely packed together, miR-22 is located ~336 kb away from 
them (17:1617197–1617281). Therefore, the distance between 
them could lead to their involvement in separate genetic and 
epigenetic events during the initiation and progression of 
breast tumorigenesis. 
As mentioned above, we found a different pattern of expres-
sion for miR-22 in breast tumors. In contrast to what we hy-
pothesized and to what we observed for miR-132 and miR-
212, we found a significant upregulation of miR-22 expression 
in breast tumors compared to that in their marginal nontu-
mor counterparts. Nevertheless, miR-22 expression levels in 
different grades and stages of malignancy were similar to 
those of miR-132 and miR-212. Interestingly, a conflicting 
role for miR-22 as an oncomiR [23] and as a tumor suppres-
sor [24-26] has been reported. In addition to the possible ef-
fects of sample grade and stage on the outcome of results, an-
other possibility should be taken into account that may ex-
plain these conflicting reports. As we have already reported 
for miR-21, the stromal content of samples can affect the out-
come of expression results [27]. This may be explained as 
miRNA expression is not confined to tumor cells, and thus 
some altered expression may be attributed to stromal cells 
within the tumor microenvironment, including cancer-asso-
ciated fibroblasts [28]. Therefore, the amount of stromal con-
tent in tumor samples may affect the outcome of results [28].
Our data revealed a consistent and noticeable downregul-
ation of miR-132, miR-212, and miR-22 in high-grade samples, 
as well as a noticeable upregulation in stage III breast tumors. 
The latter finding is in agreement with a recent report by 
Hanieh [29], in which antimetastatic properties of the miR-
212/132 cluster through SOX4 suppression in human tumor 
cells were demonstrated. In the case of miR-132, our data are 
consistent with those in a report by Zhang et al. [30], which 
indicated a critical role for miR-132 in breast cancer by sup-
pressing cell proliferation, invasion, migration, and metastasis 
via negative regulation of HN1.
Taken together, our data revealed significant expression al-
terations of miR-132, miR-212, and miR-22 in breast tumors, 
and that miR-132 may be utilized to differentiate between tu-
mor and nontumor states of breast tissue samples.
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